Page last updated: 2024-11-06

5-hydroxymebendazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-Hydroxymebendazole (5-OH MBZ) is a potent antiparasitic agent that is a derivative of mebendazole. It is a benzimidazole carbamate, a class of drugs that inhibit microtubule polymerization. 5-OH MBZ has been shown to be more effective than mebendazole against various parasitic infections, including those caused by nematodes, cestodes, and trematodes. It is believed that the hydroxyl group at the 5-position enhances its activity. The compound is being investigated as a potential treatment for various parasitic diseases, and its efficacy and safety profile are being evaluated in clinical trials. Research on 5-OH MBZ is ongoing, and its precise mechanism of action and its potential for therapeutic applications are being further investigated.'

5-hydroxymebendazole: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID43242
CHEMBL ID2059159
SCHEMBL ID3500740
SCHEMBL ID14643045
MeSH IDM0123279

Synonyms (34)

Synonym
compound 86-162
carbamic acid, (5-alpha-hydroxyphenylmethyl-1h-benzimidazol-2-yl)-, methyl ester
carbamic acid,(5-hydroxyphenylmethyl)-1h-benzimidazol-2-yl
r 19167
2-benzimidazolecarbamic acid, 5-(alpha-hydroxybenzyl)-, methyl ester
5-hydroxymebendazole
brn 4537623
5-(alpha-hydroxybenzyl)-2-benzimidazolecarbamic acid methyl ester
carbamic acid, (5-hydroxyphenylmethyl)-1h-benzimidazol-2-yl-
methyl n-[6-[hydroxy(phenyl)methyl]-1h-benzimidazol-2-yl]carbamate
3oo37v4b54 ,
60254-95-7
unii-3oo37v4b54
bdbm50388025
rac dihydro mebendazole
methyl (5-(hydroxyphenylmethyl)-1h-benzimidazol-2-yl)carbamate
carbamic acid, (5-(hydroxyphenylmethyl)-1h-benzimidazol-2-yl)-, methyl ester
r-19167
CHEMBL2059159 ,
SCHEMBL3500740
SCHEMBL14643045
carbamic acid, [5-(hydroxyphenylmethyl)-1h-benzimidazol-2-yl]-, methyl ester (9ci); r 19167
mebendazole-5-hydroxy
methyl n-{5-[hydroxy(phenyl)methyl]-1h-1,3-benzodiazol-2-yl}carbamate
methyl hydrogen {6-[hydroxy(phenyl)methyl]-1h-benzimidazol-2-yl}carbonimidate
DTXSID30975671
Q27257828
mebendazole-5-hydroxy 100 microg/ml in acetonitrile:dimethylsulfoxide
methyl (5-(hydroxy(phenyl)methyl)-1h-benzo[d]imidazol-2-yl)carbamate
CS-0082440
HY-123305
r19167
methyl n-{6-[hydroxy(phenyl)methyl]-1h-1,3-benzodiazol-2-yl}carbamate
AKOS040749981
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Calmodulin-domain protein kinase 1Toxoplasma gondiiIC50 (µMol)3.00000.23000.45000.6700AID672956
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1215966Drug level in human liver S9 fraction treated with 10 uM mebendazole after 19.80 to 20.76 mins by HPLC-MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID672956Inhibition of Toxoplasma gondii CDPK12012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1.
AID672955Inhibition of Cryptosporidium parvum CDPK12012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1.
AID1215968Drug level in human intestinal S9 fraction treated with 10 uM mebendazole 20.69 mins by HPLC-MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID1215965Drug level in human liver cytosol treated with 10 uM mebendazole after 20.80 mins by HPLC-MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
AID1215967Drug level in human intestinal cytosol treated with 10 uM mebendazole after 20.74 mins by HPLC-MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Significance of reductive metabolism in human intestine and quantitative prediction of intestinal first-pass metabolism by cytosolic reductive enzymes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (25.00)18.7374
1990's3 (37.50)18.2507
2000's1 (12.50)29.6817
2010's2 (25.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.51 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]